RecruitingNot Applicable

Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Thermal Burns

Russia30 participantsStarted 2025-10-01

Plain-language summary

This observational pilot study aims to identify criteria for evaluating the effectiveness of hemoadsorption with the Efferon LPS NEO device in pediatric burn injury. Participants will be prospectively assigned to the treatment group and compared with a retrospectively selected control group. Each patient in the treatment group will undergo two hemoadsorption sessions, each lasting 6-12 hours, with an interval of 24-120 hours between procedures. The sessions may be performed in combination with hemofiltration or hemodiafiltration at the discretion of the investigator.

Who can participate

Age range1 Year – 14 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Thermal burn of Ⅱ and Ⅲ severity with a lesion area of 40% or more (ICD-10: T20-T25, T29) * Frank index \>90 (Frank Index quantifies burn severity based on the depth and total surface area of the skin lesion) * Start of hemoadsorption no later than 5 days after admission to the ICU * The patient should receive adequate infusion therapy (at least 30 mL/kg) from the moment of inclusion in the study until the first sorption * The patient's condition allows Efferon LPS NEO therapy to be performed for at least 6 hours Exclusion Criteria: * Presence of end-stage renal disease * Acute pulmonary embolism, confirmed by CT scan * Uncontrolled bleeding (acute blood loss within the last 24 hours)

What they're measuring

ICU length of stay

Timeframe: 1-28 days

Trial details

NCT IDNCT07248930

SponsorEfferon JSC

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-12-31

Contact for this trial

Alexandr Shelehov-Kravchenko, PhD, MD

+79636564765 alexandr.shelehov@gmail.com

View on ClinicalTrials.gov More Burns trials